Novel Combination Cancer Immunotherapy Summit 2024

Welcome to the Novel Combination Cancer Immunotherapy Summit - Supercharging Immunotherapies with Rational Combinations of ICIS, OVs, Adoptive Cells and Beyond

The field of oncology is moving away from targeted monotherapies due to exhibited tumor resistance, low efficiency and off-target effects. Therefore, combination cancer immunotherapies are taking center stage as the next frontier in oncology but challenges remain before they can become the mainstream therapeutic strategy over the current standards of care.

For the first time ever, immuno-oncology pioneers will unite at the Novel Combination Cancer Immunotherapy Summit 2024, to revolutionize cancer treatments through the rational selection and development of effective and durable combination therapies with checkpoint inhibitors, ADCs, adoptive cell therapies, oncolytic viruses and beyond.

From overcoming resistance and relapse to improving patient selection, protocol design, regulatory adherence and route to market, join forces with leading experts in the field such as Merck, Pfizer and Amgen to advance your combination strategies. Stay ahead of the curve with scientific advancements that will unleash the true power of combination cancer immunotherapies by fast-tracking your pipelines towards commercially successful and therapeutically valuable assets.

Prices:
Conference + 2 Workshops - Drug Developer Pricing: USD 3097.00,
Conference + 1 Workshop - Drug Developer Pricing: USD 2698.00,
Conference Only - Drug Developer Pricing: USD 2299.00,
Conference + 2 Workshops - Academic and Non Profit Pricing: USD 2497.00,
Conference + 1 Workshop - Academic and Non Profit Pricing: USD 2198.00,
Conference Only - Academic and Non Profit Pricing: USD 1899.00,
Conference + 2 Workshops - Service and Solution Provider Pricing: USD 3997.00,
Conference + 1 Workshop - Service and Solution Provider Pricing: USD 3498.00,
Conference Only- Service and Solution Provider Pricing: USD 2999.00

Speakers: Michael Chisamore, Executive Director, Clinical Research, Merck and Co, Raj Ganesan, Executive Director, Oncology, Amgen , Yuanming Xu, Associate Director, Pfizer, Calvin Shi, Associate Director, Regulatory Affairs, Oncology, Gilead Sciences, Deb Kientop, Vice President, Clinical Operations, DEKA Biosciences, Francesca Barone, Chief Scientific Officer, Candel Therapeutics, Angelica Loskog, Chief Executive Officer and Chief Scientific Officer, Lokon Pharma AB, Geoff Stone, Director - Biotherapeutics, Exelixis , Howard Kaufman, President and Chief Executive Officer, Ankyra Therapeutics, John Hoerter, Senior Principal Scientist, Novartis AG, John Mumm, Chief Executive Officer and Co- Founder, DEKA Biosciences, Longli Zhou, Researcher, Hanson Wade, Matt Giacalone, CEO, Vaxiion Therapeutics , Oliver Van Oekelen, Physician-Scientist, Icahn school of medicine, Mount Sinai, Stefan Scherer, Chief Executive Officer, 3T Biosciences, Talia Biran, President, Oncolys BioPharma , Tony Arulanandam, Chief Executive Officer and Founder, Synaptimmune Therapeutics, Victor Cervera, Vice President - Business Development, TILT Biotherapeutics , Wayne Carter, President and Chief Executive Officer, TVAX Biomedical , William Jia, Co-founder and Chief Scientific Officer, Virogin Biotech

Others Details

URL:
Brochure: https://go.evvnt.com/2511263-2?pid=6581 

Category: Conferences | Science, Health & Medicine | Oncology